Recce Pharmaceuticals secures phase II trial safety approval for breakthrough R327G treatment
Recce Pharmaceuticals Limited recently announced significant progress in its phase II clinical trial for RECCE 327 Topical Gel (R327G), an innovative treatment for acute bacterial skin and skin structure infections (ABSSSI). An independent non-Data Safety Monitoring Board (non-DSMB) reviewed the interim safety and efficacy data, affirming R327G’s safety and tolerability. In addition, highly encouraging efficacy […]
